Enanta’s RESOLVE Trial Just Started. Your Site’s RSV Readiness Hasn’t.
Enanta dosed its first RESOLVE patient Oct 26. High-risk adult RSV outpatient capacity is already strained, here's what site...
study startup
WCG’s Activation Intelligence Targets the Document Conflict That Quietly Kills Your Startup Timeline
WCG's new Activation Intelligence tool claims to cut 20+ hours of rework per study launch by catching document conflicts...
20 Hours Back Per Activation: What WCG’s New Tool Reveals About the Real Cost of Manual Study Startup
WCG's Activation Intelligence saves 20+ hours per study activation. Here's what that number means for site startup budgets and...
The EDC Consolidation Play That Could Actually Fix Your Query Backlog
CRScube acquired Mednet in Nov 2025, uniting 84,000 site users under one AI-assisted EDC. Here's what that means for...
Fortrea’s $45M Early Phase Deal Sets a 90-Day Test for Sponsors With Active Studies
Fortrea's $45M buy of Worldwide Clinical Trials' Early Phase Services unit means active sponsors face contract novation, lab method...
When the Sponsor’s IT Goes Down, Your Trial Goes With It
Boston Scientific's August 2026 cyberattack knocked out global IT and shipping. Here's what that means for sites running active...
When Your CRO Gets Acquired Mid-Study, Your Site Feels It First
Curavit's acquisition of Lindus Health's CRO assets unifies 13,478 sites across 79 countries — but site teams will navigate...
When Your CMO Fails an FDA Inspection, Your Sites Pay the Price
Scholar Rock's BLA refiling for SMA drug apitegromab after Catalent Indiana's OAI classification shows how CMO inspection failures translate...
![Stack of documents clipped with a black binder clip on a wooden desk, with a pen and glasses nearby in sunlight] ,](https://www.clinicaltrialvanguard.com/wp-content/uploads/2026/07/your-recruitment-plan-is-failing-before-screening-even-start-750x575.png)
Your Recruitment Plan Is Failing Before Screening Even Starts
59% of sites report recruitment blocked by process inefficiencies—the bottleneck isn't patient supply, it's the workflow that never gets...
59% of Sites Are Losing Patients Before They Ever Screen — Here’s Where the Pipeline Actually Breaks
A new survey finds 59% of clinical trial sites lose eligible patients to process failures. Krishma Shah breaks down...